Latest from Medixcel

RGMBS 2026 has concluded, and Medixcel leaves the Summit with gratitude and a clear direction.

Over three days in Riyadh, we welcomed clinicians, investors and officials at our booth, and took the stage at the Life Sciences Innovation Forum (LSIF 2026), one of 23 companies from eight countries to pitch. There, together with TCT Saglik, we presented our plan to localise CAR-T cell therapy in the Kingdom.

Our sincere thanks go to Dr. Erkan Mankan, Co-Founder and CEO of TCT Sağlık, and to the entire TCT team, for standing beside us throughout. This partnership rests on trust and on one shared goal: advanced therapies within reach of the patients who need them.

We also thank the Riyadh Global Medical Biotechnology Summit, the Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center and the KSAU-HS College of Medicine for an outstanding Summit.

The Summit has ended. Our work has just begun.

We were honoured to welcome Khaled Alkhattaf, CEO of the Saudi Investment Promotion Authority (SIPA), and Majed Al Saadi, Chief Operating Officer, to the Medixcel booth during the Riyadh Global Medical Biotechnology Summit (RGMBS 2026).

The visit provided an opportunity to present the Medixcel technology ecosystem and discuss our strategic alignment with Saudi Vision 2030 and the National Biotechnology Strategy, with a focus on localising advanced therapies and gene therapy capabilities within the Kingdom.

We extend our gratitude to Mr. Alkhattaf and Mr. Al Saadi for their time and engaging exchange. Medixcel looks forward to actively supporting Saudi Arabia’s ambition to become a premier global biotechnology hub.

A transformative step toward localizing advanced cellular immunotherapy within the Kingdom of Saudi Arabia.

Medixcel has executed a strategic partnership agreement with TCT Health Technology, dedicated to transferring and localizing next-generation CAR-T cell therapy platforms and bio-manufacturing capabilities to address hematologic malignancies and complex autoimmune conditions.

Localizing these sophisticated biotherapies overcomes international cold-chain and cross-border logistics, accelerating the delivery of life-saving immunotherapies through robust domestic infrastructure.

Strategic partnerships engineering a self-reliant, innovation-driven healthcare future.

Medixcel was honoured to take part in the fourth edition of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026), held in Riyadh from 14 to 16 September 2026, together with our partner TCT.

Our sincere thanks go to Dr. Erkan Mankan, Co-Founder and CEO of TCT, for joining us in Riyadh and for his commitment to our partnership in advanced therapies.

The Summit reflected the Kingdom’s ambition under the National Biotechnology Strategy, and Medixcel is proud to contribute alongside its partners. We are grateful to the organisers and hosts: RGMBS, the Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center and the KSAU-HS College of Public Health and Health Informatics.

Advancing localised biomedical innovation and sovereign drug development within the Kingdom.

Medixcel has signed a strategic partnership agreement with Trustlife, aimed at establishing advanced national capabilities in AI-driven drug discovery, accelerating molecular screening, and optimising clinical trial development inside Saudi Arabia in alignment with international standards.

This partnership underscores our commitment to transforming the national healthcare landscape: transitioning from relying on imported therapies to nurturing localised clinical capabilities that innovate and develop within the Kingdom, contributing directly to Saudi Vision 2030. The future of healthcare, built in the Kingdom.

Empowering precision medicine and advancing biomedical data sovereignty in Saudi Arabia.

Medixcel has formalised a strategic partnership with Phenome to establish advanced national infrastructure for multi-omics profiling, integrating genomics, proteomics and metabolomics alongside clinical digital twin modelling in Riyadh.

This collaboration equips oncologists and immunology consultants with comprehensive molecular readouts that combine the genome, the proteome and metabolic pathways, to support treatment decisions tailored to each patient. Medixcel continues to work to keep advanced diagnostic laboratories, health data analytics and specialised research expertise inside the Kingdom, in support of the healthcare system and the future of personalised medicine under Vision 2030.